Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Non Operating Income (2016 - 2025)

Guided Therapeutics' Non Operating Income history spans 11 years, with the latest figure at -$508000.0 for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 330.51% to -$508000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$715000.0, a 261.11% decrease, with the full-year FY2025 number at -$824000.0, down 166.67% from a year prior.
  • Non Operating Income hit -$508000.0 in Q4 2025 for Guided Therapeutics, down from -$257000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for GTHP hit a ceiling of $555000.0 in Q3 2021 and a floor of -$508000.0 in Q4 2025.
  • Historically, Non Operating Income has averaged -$57555.6 across 5 years, with a median of -$50000.0 in 2023.
  • Biggest five-year swings in Non Operating Income: plummeted 2800.0% in 2023 and later skyrocketed 9700.0% in 2025.
  • Tracing GTHP's Non Operating Income over 5 years: stood at -$9000.0 in 2021, then skyrocketed by 222.22% to $11000.0 in 2022, then skyrocketed by 1445.45% to $170000.0 in 2023, then plummeted by 169.41% to -$118000.0 in 2024, then crashed by 330.51% to -$508000.0 in 2025.
  • Business Quant data shows Non Operating Income for GTHP at -$508000.0 in Q4 2025, -$257000.0 in Q3 2025, and -$48000.0 in Q2 2025.